Literature DB >> 3383991

The effects of perhexiline maleate on low density lipoprotein processing and cholesterol metabolism in cultured human fibroblasts.

C Candide1, J C Mazière, C Mazière, A Lageron, J Polonovski.   

Abstract

The effects of perhexiline maleate (PM, Pexid) on low density lipoprotein (LDL) processing and cholesterol metabolism were investigated after a 24 h pretreatment with the drug. Perhexiline maleate increased LDL uptake in the range 10(-6) to 10(-5) M (180% of control for 10(-5) M), whereas LDL binding and degradation were not affected. Sterol synthesis from sodium acetate was enhanced by perhexiline maleate (X 2.2 for 10(-5) M), while cholesterol esterification with oleic acid was decreased (40% of control for 10(-5) M). These effects of perhexiline on cholesterol metabolism are specific, since the synthesis of triacylglycerols from sodium acetate is not affected and since the incorporation of oleic acid into triacylglycerols is much less impaired. The decreased cholesterol esterification is accompanied by a reduction of acylcoenzyme A-cholesterol-O-acyltransferase (ACAT) activity measured in vitro on cell extracts.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3383991     DOI: 10.1007/bf00614558

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Interconversion of active and inactive forms of rat liver hydroxymethylglutaryl-CoA reductase.

Authors:  J L Nordstrom; V W Rodwell; J J Mitschelen
Journal:  J Biol Chem       Date:  1977-12-25       Impact factor: 5.157

2.  Phosphorylation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and modulation of its enzymic activity by calcium-activated and phospholipid-dependent protein kinase.

Authors:  Z H Beg; J A Stonik; H B Brewer
Journal:  J Biol Chem       Date:  1985-02-10       Impact factor: 5.157

Review 3.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

4.  Effects of Pexid on liver cell cultures. Ultrastructural and histoenzymological studies.

Authors:  A Lageron; J Scotto; M Gautier
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Evidence for phosphorylation/dephosphorylation of rat liver acyl-CoA:cholesterol acyltransferase.

Authors:  K L Gavey; D L Trujillo; T J Scallen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

6.  Calcium antagonists and low density lipoproteins metabolism by human fibroblasts and by human hepatoma cell line HEP G2.

Authors:  A Corsini; A Granata; R Fumagalli; R Paoletti
Journal:  Pharmacol Res Commun       Date:  1986-01

7.  Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia.

Authors:  M S Brown; S E Dana; J L Goldstein
Journal:  J Biol Chem       Date:  1974-02-10       Impact factor: 5.157

8.  Rapid analysis of cellular lipids without extraction.

Authors:  C Mazière; J C Mazière; L Mora; J Polonovski
Journal:  J Biochem Biophys Methods       Date:  1987-08

9.  Verapamil suppresses atherosclerosis in cholesterol-fed rabbits.

Authors:  J L Rouleau; W W Parmley; J Stevens; J Wikman-Coffelt; R Sievers; R W Mahley; R J Havel
Journal:  J Am Coll Cardiol       Date:  1983-06       Impact factor: 24.094

10.  Verapamil enhances receptor-mediated endocytosis of low density lipoproteins by aortic cells in culture.

Authors:  O Stein; E Leitersdorf; Y Stein
Journal:  Arteriosclerosis       Date:  1985 Jan-Feb
View more
  1 in total

1.  The liver metabolite S-422 of the hypolipidaemic drug benfluorex decreases cholesterol esterification in fibroblasts and monocyte-like cells.

Authors:  J C Mazière; C Mazière; M Auclair; L Mora; O Arnaud
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.